Acurx Pharmaceuticals, Inc. (ACXP) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mixed picture: significant cost reductions and decreased net losses are positive, but there's uncertainty in trial timelines and management's vague responses in the Q&A. While financial health has improved, the lack of clear guidance and potential delays in trials temper optimism. The absence of a market cap makes it difficult to gauge stock volatility, suggesting a neutral sentiment with a potential slight positive shift if trial developments progress smoothly.
Key Financial Performance
Cash The company ended the year with cash totaling $7.6 million compared to $3.7 million as of December 31, 2024. This represents an increase of $3.9 million year-over-year, primarily due to gross proceeds from purchases under the Equity Line of Credit totaling approximately $4 million for the full year of 2025.
Research and Development Expenses (Q4) For the 3 months ended December 31, 2025, research and development expenses were $0.3 million compared to $0.8 million for the 3 months ended December 31, 2024, a decrease of $0.5 million. The decrease was primarily due to a $0.2 million reduction in manufacturing costs and a $0.3 million reduction in consulting costs as a result of prior year trial-related expenses.
Research and Development Expenses (Full Year) For the 12 months ended December 31, 2025, research and development expenses were $1.8 million versus $5.4 million for the 12 months ended December 31, 2024, a decrease of $3.6 million. This was primarily due to a $2.6 million reduction in manufacturing-related costs and a $1 million decrease in consulting costs, as the prior year had higher expenses related to Phase IIb and Phase III preparation costs.
General and Administrative Expenses (Q4) For the 3 months ended December 31, 2025, general and administrative expenses were $1.3 million compared to $2 million for the 3 months ended December 31, 2024, a decrease of $0.7 million. The decrease was primarily due to a $0.3 million reduction in compensation-related costs and a $0.3 million reduction in professional fees.
General and Administrative Expenses (Full Year) For the 12 months ended December 31, 2025, general and administrative expenses were $6.3 million versus $8.7 million for the 12 months ended December 31, 2024, a decrease of $2.4 million. The decrease was primarily due to a $0.9 million reduction in professional fees, a $1.4 million reduction in share-based compensation, and a $0.4 million reduction in compensation costs, partially offset by a $0.3 million increase in legal costs.
Net Loss (Q4) The company reported a net loss of $1.6 million or $0.73 per diluted share for the 3 months ended December 31, 2025, compared to a net loss of $2.8 million or $3.29 per diluted share for the 3 months ended December 31, 2024. This represents a decrease in net loss of $1.2 million, primarily due to reductions in research and development and general and administrative expenses.
Net Loss (Full Year) The company reported a net loss of $8 million or $5.32 per diluted share for the 12 months ended December 31, 2025, compared to a net loss of $14.1 million or $17.45 per share for the 12 months ended December 31, 2024. This represents a decrease in net loss of $6.1 million, primarily due to reductions in research and development and general and administrative expenses.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Ibezapolstat clinical trial program: Launched a groundbreaking clinical trial program for ibezapolstat targeting recurrent CDI (rCDI). The trial aims to position ibezapolstat as the first agent to demonstrate clinical success in both treatment and prevention of rCDI. Phase II results showed 96% clinical cure with no recurrence in patients.
Microbiome-sparing properties: Presented new data at IDWeek in Atlanta showing ibezapolstat's microbiome-sparing properties and its potential as a class effect for DNA pol IIIC inhibitors.
Patent extension: Received a new U.S. patent for Pol IIIC inhibitors, extending protection to December 2039.
Market potential for ibezapolstat: Ibezapolstat targets a public health threat affecting 500,000 patients annually in the U.S., with a related cost burden of $5 billion, including $2.8 billion for recurrent CDI.
Financial position: Ended 2025 with $7.6 million in cash, up from $3.7 million in 2024. Raised $4 million through an Equity Line of Credit in 2025.
Cost reductions: R&D expenses decreased by $3.6 million in 2025 compared to 2024, primarily due to lower manufacturing and consulting costs. General and administrative expenses also decreased by $2.4 million.
FDA regulatory changes: The FDA's potential shift to a one-trial requirement for drug approval could favorably impact ibezapolstat's clinical development timeline.
Made in America initiative: Ibezapolstat's commercial supply chain will be entirely based in the U.S., enhancing its market appeal.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Funding Challenges: The company continues to identify and pursue funding opportunities for its Phase III clinical trial program for ibezapolstat, indicating potential financial constraints or challenges in securing adequate funding for its development programs.
Macroeconomic Environment: The company acknowledges navigating through challenging times in the macroeconomic environment, which could impact its operations and financial stability.
Regulatory Uncertainty: While the FDA's potential shift to a one-trial requirement for registration is seen as favorable, the company awaits further clarification, indicating uncertainty in regulatory pathways that could affect clinical development timelines.
Dependence on Clinical Trial Success: The company's future success heavily depends on the outcomes of its clinical trials, including the new ibezapolstat trial for recurrent CDI. Any unfavorable results could significantly impact its strategic objectives.
Competitive Pressures: The company highlights the evolving competitive profile of ibezapolstat, suggesting potential challenges in differentiating its product in a competitive market for CDI treatments.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Launch of groundbreaking ibezapolstat clinical trial program: The company announced the initiation of a new clinical trial program for ibezapolstat targeting recurrent C. difficile infection (rCDI). This trial aims to position ibezapolstat as the first agent to demonstrate clinical success in both treating CDI and preventing rCDI. The program begins with an open-label pilot trial for patients with multiple recurrent CDI, followed by a Phase III registration trial upon favorable results.
FDA's new one-trial requirement: The FDA's recent announcement of a one-trial requirement for registration could potentially allow Acurx to seek marketing approval for ibezapolstat with a single pivotal clinical trial, reducing the time and resources needed for approval.
Patent extension for Pol IIIC inhibitors: A new patent for Pol IIIC inhibitors, including ibezapolstat, was granted by the U.S. Patent and Trademark Office, extending protection until December 2039. This strengthens the intellectual property position of the company.
Funding initiatives for Phase III trials: The company is actively pursuing funding opportunities and alternative financial pathways to support the Phase III clinical trial program for ibezapolstat.
Market potential for ibezapolstat: If approved, ibezapolstat could address a significant public health issue, with approximately 500,000 CDI cases annually in the U.S., 30,000 deaths, and a $5 billion cost burden, of which $2.8 billion is related to recurrent CDI. The drug's ability to treat and prevent recurrence could shift the treatment paradigm from two agents to one.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the primary endpoint for the new recurrent CDI trial and how long is the follow-up period?
A:The primary endpoint is the prevention of recurrence, with an assessment endpoint at 8 weeks. Patients will be followed for approximately 6 months after the end of therapy to gather additional data.
Q:What is the recurrence rate for vancomycin or other treatments after 6 months?
A:Recurrence rates for vancomycin range between 20% and 40%, while anti-recurrence therapies have recurrence rates between 15% and 30% at the 8-week label indication. Data beyond 6 weeks is not standardly available.
Q:What is the cost of the recurrent CDI trial?
A:The cost of the trial is estimated to be in the range of $4 million to $5 million.
Q:When will the recurrent CDI trial start and how long will enrollment take?
A:Enrollment is expected to start in the second half of 2026 and will take approximately 12 to 15 months to complete.
Q:How does the pilot study impact the size of a potential Phase III trial for recurrent CDI?
A:The size of a Phase III trial will depend on the data from the pilot study. Current projections estimate 360 to 400 patients for a single trial in the recurrent CDI indication.
Q:Is U.S.-based manufacturing being prioritized and why?
A:Yes, U.S.-based manufacturing is being prioritized due to its importance to government agencies like BARDA. It aligns with public-private partnership goals and supports potential government stockpiling.
Q:What is the stability of ibezapolstat for stockpiling purposes?
A:Ibezapolstat has a stability of approximately 48 months to 5 years, making it suitable for stockpiling.
Q:What is the timeline for the Phase II trial and potential Phase III trial?
A:The Phase II trial is expected to fully enroll 12 to 15 months after starting in Q4 2026. The Phase III trial would start after the completion of the Phase II trial, though interim data might influence its timing.
Q:Can interim data from Phase II influence the start of Phase III?
A:Yes, interim data from the first 10 patients in Phase II could potentially influence the start of Phase III, depending on the Scientific Advisory Board's recommendations.
Q:What is the likelihood of moving from two trials to one trial for FDA approval?
A:There is optimism about moving to a single trial for FDA approval, supported by discussions with experts and recent publications advocating for this change. However, formal guidance from the FDA is still pending.
Q:Review of Unclear Management Responses
A:Management avoided providing a direct answer regarding the possibility of interim data influencing the start of Phase III, stating it would depend on the R&D team's assessment. Additionally, they used vague language when discussing the likelihood of moving from two trials to one trial for FDA approval, emphasizing optimism but lacking concrete details or commitments.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CDI recurrence
CEO Corporate
Co Founder
Corporate Secretary
DNA pol
Equity Line
Executive Chairman
Founder President
Line Credit
Medical Director
Phase II
Phase III
QA
Secretary Director
compound
diff infection
label
microbiome
month treatment
paradigm
patient CDI
pol IIIC
population
prevention CDI
prevention rCDI
product
purchase Equity
rCDI agent
registration trial
success treatment
treatment prevention
trial rCDI
ACXP Transcript
Acurx Pharmaceuticals, Inc. (ACXP) Q1 2026 Earnings Call Transcript
Positive5-12
The earnings call highlights significant progress in clinical trials, a favorable FDA one-trial requirement, and an extended patent, all potentially reducing time to market and enhancing IP protection. Financials show reduced losses and prudent expense management. The Q&A reinforces confidence in trial strategies and FDA alignment. Although macroeconomic challenges exist, the overall sentiment is positive, suggesting a potential stock price increase in the short term, especially if the market recognizes the strategic advancements and financial discipline.
Acurx Pharmaceuticals, Inc. (ACXP) Q4 2025 Earnings Call Transcript
Unknown3-13
The earnings call presents a mixed picture: significant cost reductions and decreased net losses are positive, but there's uncertainty in trial timelines and management's vague responses in the Q&A. While financial health has improved, the lack of clear guidance and potential delays in trials temper optimism. The absence of a market cap makes it difficult to gauge stock volatility, suggesting a neutral sentiment with a potential slight positive shift if trial developments progress smoothly.
Acurx Pharmaceuticals, Inc. (ACXP) Q3 2025 Earnings Call Transcript
Unknown11-12
The earnings call reveals both positive and negative aspects. On the positive side, there are significant cost reductions and potential regulatory advantages for ibezapolstat, supported by FDA designations. However, the company faces financial sustainability issues, with ongoing net losses and uncertainties in partnership timelines. The Q&A section showed management's cautious optimism but lacked concrete timelines or commitments, which could dampen investor confidence. Given these mixed signals, the stock is likely to remain stable in the short term, resulting in a neutral market reaction.
Acurx Pharmaceuticals, Inc. (ACXP) Q2 2025 Earnings Call Transcript
Unknown8-12
The earnings call presents a mixed picture: financial performance shows improvement with reduced losses and expenses, yet funding challenges and macroeconomic conditions pose risks. Despite positive regulatory guidance and potential partnerships, the lack of specific feedback from the medical community and operational cost concerns temper optimism. The neutral sentiment reflects these balanced factors, with no clear catalyst for a strong price movement.
ACXP Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
